Opthea to Present at Leerink Biopharma Conference
Ticker: OPTEY · Form: 6-K · Filed: Mar 6, 2024 · CIK: 1815620
Sentiment: neutral
Topics: conference-participation, biopharma, press-release
TL;DR
Opthea presenting at Leerink conference on eye disease therapy.
AI Summary
Opthea Limited announced its participation in the Leerink Partners Global Biopharma Conference, which took place on March 11-13, 2024. The company presented its latest developments regarding its novel biologic therapy for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
Why It Matters
Opthea's participation in this conference provides an opportunity for investors and industry professionals to learn about the company's progress in developing treatments for significant eye diseases.
Risk Assessment
Risk Level: low — This filing is an announcement of conference participation and does not contain material financial or operational updates.
Key Players & Entities
- Opthea Limited (company) — Registrant
- Leerink Partners Global Biopharma Conference (company) — Event Host
- March 2024 (date) — Reporting Period
- March 11-13, 2024 (date) — Conference Dates
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing reports that Opthea Limited will participate in the Leerink Partners Global Biopharma Conference.
When did the Leerink Partners Global Biopharma Conference take place?
The conference took place on March 11-13, 2024.
What is Opthea Limited's primary business focus mentioned in the filing?
Opthea Limited is focused on its novel biologic therapy for wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
What is Opthea Limited's principal executive office address?
Opthea Limited's principal executive office is located at Level 4, 650 Chapel Street, South Yarra, Victoria, 3141, Australia.
Which SEC form does Opthea Limited indicate it files annually?
Opthea Limited indicates it files its annual reports under cover of Form 20-F.
Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 13.5 · Accepted 2024-03-06 06:04:17
Filing Documents
- opt_leerink_conference.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 14KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-026844.txt ( ) — 206KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 03/06/2024